Voyager Therapeutics’ (VYGR) “Buy” Rating Reaffirmed at HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $25.00 target price on the stock.

Separately, Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $16.50.

Voyager Therapeutics Trading Down 8.9%

Shares of VYGR traded down $0.39 during mid-day trading on Tuesday, hitting $3.94. 1,456,620 shares of the company traded hands, compared to its average volume of 745,271. The stock has a market capitalization of $234.53 million, a price-to-earnings ratio of -1.94 and a beta of 1.32. The business has a 50-day moving average of $3.93 and a 200 day moving average of $4.19. Voyager Therapeutics has a one year low of $2.64 and a one year high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.08. The company had revenue of $13.46 million during the quarter, compared to analysts’ expectations of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%. As a group, analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the transaction, the chief executive officer owned 484,060 shares in the company, valued at approximately $1,834,587.40. This represents a 2.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 49,783 shares of company stock worth $188,694. Company insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Hedge funds have recently modified their holdings of the stock. EcoR1 Capital LLC raised its position in shares of Voyager Therapeutics by 497.2% during the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after purchasing an additional 3,332,544 shares during the period. Opaleye Management Inc. acquired a new position in Voyager Therapeutics during the fourth quarter valued at approximately $4,704,000. AQR Capital Management LLC lifted its position in shares of Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after purchasing an additional 317,927 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after buying an additional 206,758 shares during the last quarter. Finally, Altshuler Shaham Ltd bought a new stake in shares of Voyager Therapeutics in the fourth quarter valued at about $801,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.